ClinicalTrials.gg
TerminatedNCT00785772Updated Feb 3, 2021Results posted

A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment

A Phase 4 interventional study of Gabapentin and Gabapentin in Renal Impairment, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 1 site in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2021-02-03.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1
Allocation
Non-randomized
Ages
20 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Renal Insufficiency with a site in Japan — 1 open to participants now, 3 under way, 1 of them phase 3. Renal Insufficiency · Japan.

Enrollment
31st of 31
1 · median 35
Started
2010
with 3 others
Phase 4
6 of 39
none open now
Registered
8th of 39
by date
Lead sponsor
2 of 39
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 39 studies in Renal Insufficiency with a site in Japan, this one is the 31st largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2010, is one of 6 in phase 4, and was the 8th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 39 studies in Renal Insufficiency with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 20 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Renal Insufficiency with a site in Japan, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the pharmacokinetics (PK) following administration of gabapentin in Japanese epileptic patients with renal impairment to confirm if there are any clinically relevant differences between the plasma gabapentin concentration simulated by population PK model, which was used for the evidence of the dose adjustment for the patients with renal impairment, and observed plasma gabapentin concentration.

Read the detailed description

Only one subject was able to be enrolled. Given enrollment challenges to identify additional appropriate subjects, discussion was held with the Japan Pharmaceuticals and Medical Devices Agency (PMDA) and it was agreed with the PMDA to terminate this study. The study was terminated on December 14, 2010. The study was not terminated due to any safety findings.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • Gabapentin Pharmacokinetics
04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese epilepsy patients with renal impairment

Exclusion criteria

Exclusion Criteria:

  • NA
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    1: Patients with Cleatinine Clearance (CLcr) 5-14 mL/min

    Drug: Gabapentin

  • Experimental
    2: Patients with CLcr 15-29 mL/min

    Drug: Gabapentin

  • Experimental
    3: Patients with CLcr 30-59 mL/min

    Drug: Gabapentin

Interventions

06

What researchers measure

Primary outcomes

  1. Observed Plasma Gabapentin Concentration

    Plasma gabapentin concentrations were measured on Day 8 and Day 15

    Time frame: Days 8 and 15

  2. Ratio of Observed Plasma Gabapentin Concentration to Predicted Plasma Gabapentin Concentration Based on Population Pharmacokinetics Model

    Ratio of observed plasma gabapentin concentration to predicted plasma gabapentin concentration based on population pharmacokinetics model were calculated on Day 8 and Day 15, respectively.

    Time frame: Days 8 and 15

  3. Ratio of Observed Plasma Gabapentin Concentration to Individual Predicted Plasma Gabapentin Concentration

    Ratio of observed plasma gabapentin concentration to individual predicted plasma gabapentin concentration were calculated on Day 8 and Day 15, respectively.

    Time frame: Days 8 and 15

07

Results

Posted Apr 27, 2011
Limitations and caveats
The study was completed with an enrollment of 1 subject because prolongation of the study period or a change in the inclusion criteria (the upper limit of age was deleted) did not lead to further enrollment of subjects.

Participant flow

Study Initiation Date and Completion Dates: 16 March 2010 to 1 April 2010 Study Center: 1 center in Japan

Participant flow — Overall Study
MilestoneGabapentin
Started1
Completed1
Not completed0

Outcome measures

PrimaryObserved Plasma Gabapentin Concentration

Plasma gabapentin concentrations were measured on Day 8 and Day 15

Time frame:
Days 8 and 15
Reported as:
Mean · µg/mL
Observed Plasma Gabapentin Concentration
µg/mLGabapentin
Day 838.40 (38.40 to 38.40)
Day 1544.64 (44.64 to 44.64)
PrimaryRatio of Observed Plasma Gabapentin Concentration to Predicted Plasma Gabapentin Concentration Based on Population Pharmacokinetics Model

Ratio of observed plasma gabapentin concentration to predicted plasma gabapentin concentration based on population pharmacokinetics model were calculated on Day 8 and Day 15, respectively.

Time frame:
Days 8 and 15
Reported as:
Number · Ratio
Ratio of Observed Plasma Gabapentin Concentration to Predicted Plasma Gabapentin Concentration Based on Population Pharmacokinetics Model
RatioGabapentin
Day 82.16
Day 152.59
PrimaryRatio of Observed Plasma Gabapentin Concentration to Individual Predicted Plasma Gabapentin Concentration

Ratio of observed plasma gabapentin concentration to individual predicted plasma gabapentin concentration were calculated on Day 8 and Day 15, respectively.

Time frame:
Days 8 and 15
Reported as:
Number · Ratio
Ratio of Observed Plasma Gabapentin Concentration to Individual Predicted Plasma Gabapentin Concentration
RatioGabapentin
Day 81.15
Day 151.37

Adverse events

Collected over From Day -7 (informed consent) until 28 days after the end of study treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gabapentin—0/1 (0%)0/1 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participant)Gabapentin
<=19 years0
20-64 years1
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Gabapentin
Female0
Male1
08

Study locations

1 site
  • Pfizer Investigational Site
    Saijyo-shi, Ehime, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2008
First posted
Nov 5, 2008
Start
Mar 2010
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results first posted
Apr 27, 2011
Last update
Feb 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00785772
Responsible party
Sponsor
First posted
Nov 5, 2008
Start date
Mar 2010
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Apr 27, 2011
Last update
Feb 3, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion